Indications and dosage of brigatinib

Brigatinib (Brigatinib) is an important targeted therapy drug for non-small cell lung cancer, especially suitable for ALK-positive patients. With its excellent efficacy and relative safety, this drug has brought new treatment options to patients with lung cancer.

In terms of indications, brigatinib is mainly used to treat ALK-positive locally advanced or metastatic non-small cell lung cancer. For these patients, brigatinib can significantly inhibit the growth and spread of tumor cells, prolong survival and improve quality of life. In addition, it is also suitable for patients who have previously received crizotinib but have progressed or are intolerant, showing good therapeutic effects.

Regarding usage and dosage, the recommended starting dose of brigatinib is 90 mg once daily, orally. Patients should take medication under the guidance of a doctor and make sure to take it on time and in the right amount. During the initial 7-day cycle, if the patient tolerates it well and does not experience serious adverse effects, the dose can be increased to 180 mg once daily, which is the standard maintenance dose of brigatinib. During the medication process, patients should pay close attention to the body's reaction and promptly report any discomfort or abnormalities to the doctor.

At the same time, the taking of brigatinib is not affected by food, and patients can choose to take it with food or on an empty stomach. However, because brigatinib is sensitive to light, patients should avoid prolonged exposure to the sun and take necessary sun protection measures during treatment and for a period of time after discontinuation of treatment.

In general, brigatinib, with its unique indications and clear usage and dosage, provides an effective treatment forALK-positive non-small cell lung cancer patients. Patients should strictly follow medical instructions during use to ensure the safety and effectiveness of the drug, so as to maximize the therapeutic effect of brigatinib.